| Title |
The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa
|
|---|---|
| Published in |
PLOS ONE, June 2010
|
| DOI | 10.1371/journal.pone.0010313 |
| Pubmed ID | |
| Authors |
Lesong Conteh, Elisa Sicuri, Fatuma Manzi, Guy Hutton, Benson Obonyo, Fabrizio Tediosi, Prosper Biao, Paul Masika, Fred Matovu, Peter Otieno, Roly D. Gosling, Mary Hamel, Frank O. Odhiambo, Martin P. Grobusch, Peter G. Kremsner, Daniel Chandramohan, John J. Aponte, Andrea Egan, David Schellenberg, Eusebio Macete, Laurence Slutsker, Robert D. Newman, Pedro Alonso, Clara Menéndez, Marcel Tanner |
| Abstract |
Intermittent preventive treatment in infants (IPTi) has been shown to decrease clinical malaria by approximately 30% in the first year of life and is a promising malaria control strategy for Sub-Saharan Africa which can be delivered alongside the Expanded Programme on Immunisation (EPI). To date, there have been limited data on the cost-effectiveness of this strategy using sulfadoxine pyrimethamine (SP) and no published data on cost-effectiveness using other antimalarials. |
Mendeley readers
The data shown below were compiled from readership statistics for 162 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Ethiopia | 1 | <1% |
| Portugal | 1 | <1% |
| Australia | 1 | <1% |
| Botswana | 1 | <1% |
| Unknown | 156 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 38 | 23% |
| Researcher | 34 | 21% |
| Student > Ph. D. Student | 20 | 12% |
| Student > Doctoral Student | 12 | 7% |
| Lecturer | 11 | 7% |
| Other | 28 | 17% |
| Unknown | 19 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 31% |
| Social Sciences | 15 | 9% |
| Agricultural and Biological Sciences | 13 | 8% |
| Nursing and Health Professions | 12 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Other | 37 | 23% |
| Unknown | 26 | 16% |